1Y Target$57.10Near-term target
5Y Target$65.52Compound horizon
10Y Target$96.30Long-dated conviction
FCF$5.1bTTM · 03/26B+FCF $5.1b — strong cash profile, above most peers · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+66.7%TTM YoYARevenue +66.7% — hypergrowth, top decile
D/E0.13A-D/E 0.13 — conservative leverage, strong balance sheet
P/E11.2xA-P/E 11.2 — cheap relative to market and most sectors
PEG2.04CPEG 2.04 — expensive relative to growth rate
Why now
Gold · market cap $68.3b. Down 26% from 52-week high of $54.69 — deep drawdown territory. Revenue growing +67% — in hypergrowth territory. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $57.10 (implying +40% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 25% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $68.3b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Reserve-replacement treadmill — every barrel or ounce extracted has to be replaced through exploration or acquisition; underspending on replacement reserves shows up in production declines 2-3 years out.
Horizon
1-3 yr $57.10 (16-analyst consensus) — fundamentals + valuation re-rating. 5 yr $65.52 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $96.30 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.